Atlas
Back to RCM
Legal / Service Provider·RCM

Jill Radloff

Partner (led team advising Infinx on its $96M acquisition of i3 Verticals' Healthcare RCM business) at Stinson LLP

Minneapolis, Minnesota, USA

JR
LinkedIn
Why they matter

She quarterbacked the legal side of the most recent major healthcare RCM carve-out (Infinx/i3 Verticals, $96M) and knows the sector's deal mechanics firsthand.

Background

Jill Radloff is a corporate partner at Stinson LLP in Minneapolis focused on M&A and corporate finance in highly regulated industries, particularly insurance and healthcare. A summa cum laude graduate of the University of Minnesota Law School and former Eighth Circuit clerk to Judge James B. Loken, she has spent her career guiding strategic buyers, mutual insurers, and PE-backed companies through complex transactions. In May 2025 she led the Stinson team advising Infinx on its $96M acquisition of i3 Verticals' Healthcare RCM business.

Notable deals

  • 2025
    Led the Stinson team advising Infinx Healthcare on its $96M all-cash acquisition of i3 Verticals' Healthcare Revenue Cycle Management business
  • 2020
    Counseled Key Surgical through its sale to Water Street Healthcare Partners and Water Street's subsequent sale of Key Surgical to STERIS
  • 2017
    Represented Federated Mutual Insurance Company in its acquisition of Granite Re, an Oklahoma surety bond insurer, plus numerous surplus note investments

Call-prep brief

Jill Radloff — Partner, Stinson LLP (Minneapolis)

Background

  • Corporate finance and M&A partner at Stinson LLP; summa cum laude JD from University of Minnesota Law School (2000); clerked for Judge James B. Loken, U.S. Court of Appeals for the Eighth Circuit.
  • Deep specialization in regulated industries: health plans, property & casualty insurance, healthcare services, agribusiness, and manufacturing.
  • Recognized in *Best Lawyers in America* (2023–2026) and received the 2023 *Minnesota Lawyer* Top Women in Law award.

Current focus & recent moves

  • In May 2025 she led the Stinson team advising Infinx on its $96M carve-out acquisition of i3 Verticals' Healthcare RCM business — a structured equity purchase of subsidiaries with associated proprietary technology, signed and closed contemporaneously.
  • Repeat counsel to healthcare and insurance clients on PE exits: Key Surgical (sale to Water Street Healthcare Partners, then to STERIS) and Federated Mutual (Granite Re acquisition).

What she cares about / sensitivities

  • Regulatory and compliance risk in healthcare transactions — she works both transactional and regulatory angles.
  • She is bound by client confidentiality on Infinx and other active clients; keep questions structural, not client-specific.

Questions to ask

  1. What diligence issues most often reprice or kill healthcare RCM carve-outs — payer contract consents, data/PHI separation, or TSA complexity?
  2. How are buyers structuring RCM deals now — equity carve-outs versus asset deals — and why?
  3. Which regulatory or compliance trends (billing, AI in coding, state privacy laws) should a new RCM investor underwrite?

Outreach draft

Subject
Healthcare RCM deal structuring — quick call?
Hi Jill, I'm on the investment team at a private equity firm currently building a thesis around healthcare revenue cycle management. Your work leading the Infinx acquisition of i3 Verticals' RCM business caught our attention — few advisers have recent, firsthand experience with carve-outs in this exact space. We'd value 30 minutes to hear your perspective on how RCM transactions are being structured today and the diligence issues that matter most, strictly at the market level rather than anything client-specific. We're also always looking to build relationships with counsel ahead of future transactions. Would a call in the next couple of weeks work? Best regards, [NAME]

Linked companies

Sources